-
BIAL PORTELA & CIA
- Global Marketing Director - CNS
2012 - maintenant
* Spearheaded the Bial CNS portfolio launch expansion in the German and UK markets.
* Developed strategic and operational plans to strengthen existing portfolio as well as reach out to new markets.
* Conceptualized and implemented marketing campaigns and profit targets for the antiepileptic franchise.
* Actively contributed as a member of the European Epilepsy team (with Eisai Europe).
Key Accomplishments:
* Grew revenue across sales base by 15 million Euros in Portugal and Spain. ;
-
UCB PHARMA
- Associate Global Brand Director
2009 - 2012
* Developed and executed worldwide marketing and operational campaigns for Neupro (rotigotine) trans-dermal delivery dopamine agonist, a drug for those suffering of Parkinson's disease and Restless Leg Syndrome.
* Conducted periodic business dives leading to improved country business diagnostics, which guided affiliates with research methodologies and strategic preparation.
* Supported operational lifecycle and launch readiness, which resulted in successfully multi-country product launches in Europe, Asia, and America.
Key Accomplishments:
* Received a UCB Excellence Star Gold Award for efforts related to Neupro Deep Dive Germany initiative and Leganto partnership.
* Led the co-branding project in Germany with Leganto on an interim assignment base, and achieved all pre-set goals.
* Developed and piloted global, innovative customer targeting model in several EU countries by providing recommendations supporting implementation. ;
-
UCB Pharma Canada Inc. - Based in Atlanta GA (US)
- Global Brand Manager CNS Neupro (rotigotine) –
2008 - 2008
Responsible for the Global marketing direction of the Parkinson and RLS in the CNS Business Unit.
• Focus my responsibilities in the EU 5 countries + US.
• Guidance to National Marketing teams, provision of on market specific requirements.
• Brand expansion, marketing consistency, product development, local brand plans, and life cycle management strategy.
-
RGL PHARMA STRATEGY CONSULTING
- Principal Consultant
2006 - 2008
* Established a boutique strategic consulting practice by working through exclusive partnerships in the USA and EU.
* Formed strong working relationships with a variety of clients, including Euro RSCG (U.S.), Roche Canada, GSK Canada, Orion Pharma, ProPharma Canada, Sankyo (U.S.), and TechnoFarma International.
Key Accomplishments:
* Deliver strategic and tactical consulting solutions within the Canadian pharmaceutical industry. New Product Portfolio Launch, New Product Launch Marketing and Sales strategy consulting OTC and Rx products. (Anti-infective, Pain Killers, Dermatology and GI).
* RX/OTC Sales Structure. Field force dimension analysis, portfolio analysis, executive coaching in pharmaceutical marketing. Sales Force contractor
* Strategic Consultant with Euro RSCG (US) and the Swat Team Inc. (NY USA)
OSCAR VIRGILIO, PAGE 3
-
Boehringer Ingelheim
- Team Leader - Global Marketing CV
Paris Cedex 13
2005 - 2006
* Responsible for the worldwide marketing of Micardis (telmisartan), intended to treat essential hypertension.
* Managed the sale profit targets for the global franchise.
* Designed, implemented, and evaluated consumer programs for hypertension implementation in Japan, U.S. Germany, Spain, and Mexico.
* Managed a large executive international management team, responsible for maximizing brand business growth opportunities in Europe, Asia, and North America.
* Managed product lifecycle.
Key Accomplishments:
* Increased global sales from $840 million to $1.3 billion.
* Maximized brand exposure, re-positioning, communication, image, value-added initiatives, and regional resources deployment.
* Co-negotiated and chaired an EU and global co-promotion initiative with Bayer AG and GSK, resulting in a global increase in revenue of $230 million. ;
-
Boehringer Ingelheim
- CV/CNS Group Product Manager
Paris Cedex 13
2002 - 2004
Group Product Manager, CV, NSDAIS and CNS Team leader franchises responsible
* Total portfolio managed annual sales $ 93 Million ;
* Outpaced category growth 3 years running Micardis to fastest growing ARB in Canada, Mirapex to a dominant leadership position in the dopamine agonist market. Market Share 80%+ (CNS Parkinson).
* Drove 200% increase in sales of Mobicox (meloxican) a novel COX 2 painkillers, in last two years before generalization using a contract sales force.
* Implemented a successful value added program that set the standard for patient management with more than 45,000 physician-driven patient enrollments. Program drove 92% average patient retention level after 12 months.
* Negotiated and chaired a Canadian co-promotion initiative with GSK for Micardis.
* Responsible for the local management team (4 Product Managers and Special Sales Team coordination 12 SSRs). ;
